Madison Avenue Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Madison Avenue Partners’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-417,427	Closed	-$24.5M	–	23
2023 Q4	$24.5M	Buy	+417,427	New	+$23.5M	3.46%	9

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Madison Avenue Partners's MRTX Position: Q1 2024 in Review

Madison Avenue Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 417,427 shares — an estimated $24.5M sold.

Madison Avenue Partners first reported a position in MRTX in Q4 2023 and held it in 1 quarter. The position peaked at $24.5M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Madison Avenue Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Madison Avenue Partners sold 417,427 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $24.5M.
Madison Avenue Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
Madison Avenue Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $24.5M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Madison Avenue Partners's 13F filing for Q1 2024, filed 15 May 2024.